Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.biopha.2021.111980 http://scihub22266oqcxt.onion/10.1016/j.biopha.2021.111980 34364043!8318692!34364043     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Pharmacother 2021 ; 142 (ä): 111980 Nephropedia Template TP {{tp|p=34364043|t=2021. Interleukin-17A (IL-17A): A silent amplifier of COVID-19 |pdf=|usr=}}{{34364043}} gab.com Text Interleukin-17A (IL-17A): A silent amplifier of COVID-19 JO: Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34364043 #FOAvip One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy. Twit Text FOAVip Interleukin-17A (IL-17A): A silent amplifier of COVID-19 ????Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34364043 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34364043 #FOAvip English Wikipedia <ref>{{Cite pmid|34364043}}</ref> Interleukin-17A (IL-17A): A silent amplifier of COVID-19 #MMPMID34364043 Maione F; Casillo GM; Raucci F; Salvatore C; Ambrosini G; Costa L; Scarpa R; Caso F; Bucci M Biomed Pharmacother 2021[Oct]; 142 (ä): 111980 PMID34364043show ga One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy. |*COVID-19 Drug Treatment[MESH] |*COVID-19/diagnosis/immunology[MESH] |*Cytokine Release Syndrome/etiology/immunology[MESH] |*Interleukin-17/blood/immunology[MESH] |Biomarkers/blood[MESH] |Disease Progression[MESH] |Drug Discovery[MESH] |Humans[MESH] |Inflammation Mediators/metabolism[MESH]Interleukin-17A (IL-17A): A silent amplifier of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing